Value Antiproteinuric Effects From Vitamin D Derivatives in Patient With Chronic Kidney Illness and the Lack of Vitamin D

• Status: Unknown status
• Trial end date: 2013-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the value the additional antiproteinuric effects of vitamin D derivatives treatment, in patients with Chronic Kidney Illness phase II-IV, with lack of vitamin D and residual proteinuria higher 0,5 grams/day.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hospital Universitario de Canarias
• Treatments: Calcifediol; Ergocalciferols; Vitamin D; Vitamins

Criteria

Inclusion Criteria:

• Male/female Patients older 18 years old

• Patients have signed written informed consent

• Chronic Kidney Illness phase II-IV plus residual proteinuria >0,5 grams/day (two or more consecutive occasions) and plus beta blockers treatment from AARS during al least 3 months.

• Serum levels of calcifediol in the lack of level (15-30 ng/ml).

Exclusion Criteria:

• Bad control of high blood pressure (higher or same 180/110 mmHg)

• Bad control of diabetes (HbA1c higher 9,5 in the last three months period)

• Hypercalcemia (<10,2 mg/dL) o hyperphosphatemia(>5,5 mg/dL), CaxPO4>50, hypercalciuria (urin Ca/Cr quotient > 0,15)

• Vitamin D treatment or any analogous

• Hepatic failure ( AST o ALT > 3 times higher than normal limit)

• medical history of poor nutrient intestinal absorptions or chronic diarrhea

• Active nephrolithiasis

• Treatment with medication wich can change vitamin D metabolism (phenobarbital, phenytoin, rifampicin)

• Participation in other Clinic Trial in 3 last months

• Active Alcoholism

• Neoplasia precedent (except cutaneous no melanoma)

• Pregnant women or while breastfeeding

• Vitamin D hypersensitivity or any its excipient hypersensitivity

• Any other condition from Research